what they said (Hover the mouse cursor over underlined words for more info)

SAN DIEGO | Diabetic men with low testosterone levels could possibly find another advantage in taking rosiglitazone (Avandia), according to results of a preliminary study presented at the annual meeting of the Endocrine Society here.

The original article can be found at: http://www.medicalpost.com/mpcontent/article.jsp?content=20050629_204940_5452

The original article can found in the Media Doctor archives.

how did it rate? (more information)

what we said (Hover the mouse cursor over underlined words for more info)

This story about the benefits of rosiglitazone for central obesity describes the potential benefits in terms of surrogates markers such as hemoglobin A1C, or body weight.

However, the clinical significance of the difference of 0.02 kg in waist-hip is not related to clinical health outcomes. According to the article, treatment with this drug can increase testosterone levels, decrease central obesity and possibly reduce the incidence of heart disease. There are a lot of numbers thrown about showing the effectiveness of the medication but there is no evidence presented of any clinical benefit. In fact, the drug could be associated with overall weigh gaint. Other or serious side effects of the drug are not even considered.

public forum

voice your opinion in the forum

• All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
• If you provide your email address it will not be displayed to the general public.
• Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
• Required fields are marked with an asterisk (*).